Chris Nasveschuk, Ph.D., joined C4 Therapeutics in February 2016 and serves as our Senior Vice President of Chemistry. Previously, Chris was Medicinal Chemistry Group Leader at the Broad Institute, where he led a group of medicinal chemists in projects in the cancer, metabolism, and autophagy disease areas. Prior to the Broad, Chris was an integral member of the team at Constellation Pharmaceuticals where he co-invented the EZH2 inhibitor CPI-1205 and helped to discover the BET inhibitor pelabresib (CPI-0610). Chris holds a Ph.D. in Organic Chemistry from Colorado State University and a B.S. in Chemistry from Middlebury College.